Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: enervestor who wrote (580)	1/25/2000 3:01:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

At this point it is very hard to sort out who really has the significant IP in the genome. INCY, HGSI and CRA each claim to have most everything, and they are clearly not all right. INCY, and to a lesser extent HGSI, have had pharmas banging away at their data for a while, and they have contractual agreements with these pharmas that may well turn out to be more significant than their patent claims. In general, you'll find a generally pro-INCY perspective on SI, perhaps partially due to Rocketman and the VD thread. People generally dislike HGSI, partly because of the hype, and (misguidedly at least in retrospect) have avoided CRA altogether. Everyone here loves MLNM, of course. <g> Peter

To: enervestor who wrote (580)	1/25/2000 3:22:00 PM
From: enervestor	Read Replies (3) \| Respond to of 52153

Comments on dichotomy of today's markets: On a note indirectly sorta someday related to biotech valuation, it's amusing to me how different segments of the investing public view things. After discussing CRA, INCY, HGSI, MLNM, etc. and the prices they are trading at, here is Proctor and Gamble racing along at a 3%growth rate. When they try to buy some pharma to speed things up even more, the market throws a fit. If I were a long term PG shareholder, I would gladly trade a quarterly charge and maybe some short-term indigestion for a stronger, more diversified company down the road. As big pharma partners of biotechs, they would gain from all the genomic discoveries used on us aging babyboomers, but noooo, it might cause them a temporary disruption of their breathtaking growth rate.